PharmaShots | Incisive News in 3 Shots

Subscribe Now

HOOKIPA

HOOKIPA Reports the First Patient Dosing in P-Ib Study of HB-500 to Treat HIV

HOOKIPA Reports the First Patient Dosing in P-Ib Study of HB-500 to Treat HIV

July 2, 2024

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)

January 5, 2023

HOOKIPA and Roche Enter into a License Agreement to Develop HB-700 and Arenaviral Immunotherapies for KRAS-Mutated Cancers

HOOKIPA and Roche Enter into a License Agreement to Develop HB-700 and Arenaviral Immunotherapies for KRAS-Mutated Cancers

October 21, 2022

HOOKIPA Entered into an Amended and Restated Collaboration and License Agreement with Gilead to Develop Arenaviral Immunotherapies for HIV

HOOKIPA Entered into an Amended and Restated Collaboration and License Agreement with Gilead to Develop Arenaviral Immunotherapies...

February 16, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us